Biotech Values

[urche]

EXEL

jq,

I suspect the reality is not so black and white as EXEL never found the proper dosage in the first place.
Part of the purpose of early stage studies is dose finding. Especially dealing with widely heterogeneous cancer types, it is likely there is no one "proper" or ideal dose. For an 80 yo man with metastatic prostate cancer more than likely to die from another disease, the optimal dose may be much lower than for a younger person with metastatic renal cell carcinoma who has already failed prior treatments. It has much to do with optimizing benefit and risk. So, I don't fault them for trying multiple doses at this stage.

By the way, I share your wish that EXEL finds a big partner or buyer. The challenges ahead are enormous and risky.
Urche